BioHealthonomics

BioHealthonomics is an R&D biotech&healthcare co. that will develop a product for the treatment and prevention of migraines, PD and AD.

BioHealthonomics Inc. is a research and development biotechnology & healthcare company that will develop and commercialize both a product and a proprietary protocol for the treatment and prevention of migraine headaches, Parkinson’s disease and Alzheimer’s disease. The National Headache Foundation estimates that US businesses lose $50 billion each year because of absenteeism, reduced employee productivity, and medical expenses caused by headaches. (JD Bartleson, Treatment of Migraine Headaches, Mayo Clin. Proc. 1999; 74; 702-708). It is the 10th most disabling disorder worldwide. Parkinson’s Disease is one of the most common neurologic disorders, affecting approximately 1% of individuals older than 60 years and causing progressive disability that can be slowed, but not halted, by treatment. Despite extensive research in the area of PD, the precise pathogenesis remains largely unknown. Parkinson’s Disease is characterized by motor and non-motor (cognitive and limbic) deficits. The economic burden of Parkinson's disease is at least $14.4 billion a year in the United States, and the prevalence of Parkinson's will more than double by the year 2040. Alzheimer’s disease is an irreversible, progressive brain disease that slowly destroys memory and thinking skills, and eventually even the ability to carry out the simplest tasks. In most people with Alzheimer’s, symptoms first appear after age 60. Estimates vary, but experts suggest that as many as 5.1 million Americans may have Alzheimer’s disease. With the first of the baby boomer generation now turning 65, the U.S. population aged 65 and over is expected to double by 2030. Although Alzheimer’s is not normal aging, age is the biggest risk factor for the disease. Taken together, these factors will result in more and more Americans living with Alzheimer’s - as many as 16 million by 2050, when there will be nearly one million new cases each year. Caring for people with Alzheimer’s will cost all payers - Medicare, Medicaid, individuals and private insurance -- $20 trillion over the next 40 years. In 2012, the economic burden is estimated to be $200 billion in direct costs for those with Alzheimer’s.